Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cholangiocarcinoma × futibatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2 Neoplasm Metastasis 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Advanced and Metastatic Urothelial Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 52 Cisplatin 29 Oxaliplatin 24 Fluorouracil 19 lenvatinib 18 durvalumab 18 Capecitabine 16 Leucovorin 13 pembrolizumab 9 apatinib 9 tislelizumab 7 sintilimab 6 pemigatinib 6 Radiotherapy 6 Panitumumab 6 Floxuridine 6 Albumin-Bound Paclitaxel 6 tremelimumab 5 olaparib 5 Taxes 5 Specimen Handling 5 Magnetic Resonance Spectroscopy 5 Folfox protocol 5 Drug Therapy 5 Bevacizumab 5 camrelizumab 4 Nivolumab 4 Irinotecan 4 Carboplatin 4 Biopsy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05727176 2025-12-29

FOENIX-CCA4

Taiho Oncology, Inc.

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡